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Modelingow effectively a CD8+ T cell inducing vaccine controls SHIV-89.6P infection in
rhesus macaques at a range of challenge times post-vaccination. To this end, twenty eight Mamu-A⁎01+
rhesus macaques were given replication incompetent human serotype 5 adenovirus vector expressing
SIVmac239 gag DNA and boosted 24 weeks later. Groups of 4 monkeys were then challenged with SHIV-
89.6P at 1, 3, 6, 12, and 24 weeks after the boost. We compared the kinetics of viral load, CD4+ and virus-
speciﬁc CD8+ T cells in these macaques. Measurements of CD8+ T cells taken before challenge show an
exponential decay between 1 and 12 weeks following vaccination (pb0.0001). After week 12, no further
decay was observed. Twenty of 24 vaccinated animals maintained more CD4+ T cells and kept their viral load
at least one order of magnitude lower than the control animals throughout the chronic phase of the study. All
24 vaccinated animals survived the duration of the study. The viral and T cell kinetics over the ﬁrst two weeks
differed between the vaccinated groups, with more recent vaccination improving the early control of virus
(p-value=0.027). The rates of virus speciﬁc CD8+ T cell expansion were greater in animals having higher viral
loads at one week (r=0.45, p=0.029), suggesting that the kinetics of early viral load may have a role in virus
speciﬁc CD8+ T cell generation, although these early differences did not lead to different clinical outcomes
within the vaccinated animals.
Published by Elsevier Inc.IntroductionHIV infects 33 million people worldwide (UNAIDS and WHO,
2007). Even as treatment for HIV advances and reaches larger
numbers of individuals, the risk of transmitting the disease remains
high, particularly during acute infection, and a vaccine is the best hope
to curb the spread of infection. However, vaccines based on CD8+ T cell
immunity have had mixed success: current results in nonhuman
primate models, especially with SHIV challenge, indicate that these
vaccines may attenuate the severity of infection, but do not prevent
infection itself (Johnston and Fauci, 2007). We have previously
demonstrated that the inability of CD8+ T cells to prevent the
establishment of persistent SHIV infection occurs because they do
“too little too late” to control early viral growth in the ﬁrst 10 days
after infection (Davenport et al., 2004). This was subsequently
conﬁrmed in SIVsmE660 and SIVmac239 infection (Abdel-Motal et
al., 2005; Reynolds et al., 2005).nc.One explanation for the inability of CD8+ T cells to control early
infection is that there are too few of them to efﬁciently detect and kill
infected cells. But even very high numbers of virus-speciﬁc CD8+ T
cells do not lead to earlier viral control (Davenport et al., 2004, 2007;
Shiver et al., 2002). Higher levels of speciﬁc CD8+ T cells before
infection do, however, lead to a better prognosis in chronic infection
(Davenport et al., 2005). This suggests that rather than absolute cell
number, some aspect of the quality or activation state of CD8+ T cells
may be essential for viral control.
The time period between the last vaccine boost and challenge with
infectious virus may impact the state or quality of CD8+ T cells.
Recently activated T cells may be functionally different from cells that
encountered their cognate antigen a longer time ago. For this reason,
we were interested in studying how the kinetics of SHIV primary
infection in recently vaccinated macaques differ from the kinetics in
macaques vaccinated some time previously. How long a vaccine
confers protection after administration is a crucial question that will
determine the frequency a person needs to be vaccinated andmay also
have implications for the design of vaccines (Anderson et al., 2005).
Here we analyze the kinetics of virus and vaccine-induced speciﬁc
immunity in a set of vaccinated Mamu-A⁎01+ rhesus macaques
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boost. A high level of CD8+ T cell immunity was induced by the vaccine
soon after immunization, which decayed during the ﬁrst 12 weeks
post-boost and then stabilized. Thus, the level of protection afforded
by a vaccination regimen may depend on either the magnitude of the
response at different times since vaccination or the quality of these
responses (Anderson et al., 2005).
Our quantitative analysis of viral kinetics suggests that recent
vaccination better controls virus early in primary infection. We
speculate that recent antigen exposure may alter the phenotype,
function, or location of the responding cells, with an effect in reducing
viral load. Better early control did not, however, affect the long term
outcome in SHIV 89.6P infection.
Results
Kinetics of infection
Fig. 1 shows the average viral load, CD8+ p11CM+ T cell counts, and
CD4+ Tcell depletion, the numberof CD4+ Tcells/μL divided by the CD4+
T cell count on the day prior to infection, for each vaccination group.
Compared with the control group, all vaccinated groups have a lower
peak and chronic stage viral load, retain a larger proportion of CD4+ T
cells, and have more antigen speciﬁc CD8+ p11CM+ T cells.
All but four vaccinated animals (one in group A, two in group D,
and one in group F) were able to keep their chronic viral levels at least
one order of magnitude lower than the control animals' viral loads,
with several vaccinated animals having viral loads below the limit of
detection (50 virions/μL) for the duration of the study. At approxi-
mately six months (178 days) post-infection, the distribution of theFig. 1. Acute infection proﬁles differ with challenge time (proﬁles are averaged over the four m
f) CD4+ T cell depletion, i.e., the number of CD4+ T cells/μL divided by the CD4 count on the da
vaccinated animals, groups E and F.viral loads of individual animals did not differ between the
vaccinated groups (p=0.48) (Fig. 1). Nevertheless, there was a
signiﬁcant positive correlation (r=0.72, p=1.3×10−5) between the
peak viral load in the acute phase of infection and the viral load on
day 178, stressing the importance of making vaccines that better
control early infection.
Effect of time to challenge on speciﬁc CD8+ T cell kinetics
The maximum number of p11CM+ CD8+ T cells before challenge
was observed one week after vaccination and boost (median=173
cells/μl). Subsequently, for the ﬁrst 12 weeks after vaccination and
boost, but prior to SHIV-89.6P challenge, the number of p11CM+ CD8+
T cells declined exponentially with a half-life of four weeks (Fig. 2)
(pb0.0001). Interestingly, we could not detect a further reduction in
CD8+ p11CM+ T cell levels between weeks 12 and 24, perhaps
indicating the attainment of a steady state level (both the 12 and
24 week groups have a median of 4 cells/μL).
As noticed before (Abdel-Motal et al., 2005; Davenport et al., 2004,
2005; Reynolds et al., 2005), after SHIV/SIV challenge there is a time
lag before an expansion in antigen speciﬁc p11CM+ CD8+ T cells can be
measured. As in (Davenport et al., 2005), the length of the time lag, ton,
was correlated with the initial number of p11CM+ CD8+ T cells across
vaccinated groups: the higher the number of CD8+ p11CM+ T cells at
challenge, the longer it took for an expansion to be detected (r=0.48,
p=0.018). Because the number of p11CM+ CD8+ T cells at challenge
falls with time since vaccination, we also found that ton negatively
correlates with challenge time in groups B–E, the groupswhich showa
decay of baseline p11CM+ CD8+ T cells from week 1 to 12 (r=−0.53,
p=0.033).onkeys in each group): a) and d) viral load, b) and e) CD8+ p11CM+ T cells/μL, and c) and
y prior to infection. The viral load at day seven is signiﬁcantly lower in the more recently
Fig. 2. Decay and plateau of CD8+ p11CM+ T cells after vaccination, individual animals
(colored circles) and group median (black diamonds) are shown. In the boosted and
vaccinated groups, the animals' antigen-speciﬁc CD8+ T cells drop monotonically with
time between week 1 and 12. Group A measured at 24 weeks post-boost has the same
number of CD8+ T cells as Group B, measured at 12 weeks.
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We next investigated the relationship of CD4+ T cell depletionwith
virus and with CD8+ p11CM+ T cell kinetics. We found a positive
correlation between the peak viral load and the amount of CD4+ T cell
depletion that occurred between days 1 to 25 (r=0.88, p=1.0×10−9;
and r=0.80, p=3.8×10−6 considering only the vaccinated groups),
consistent with our previous study (Davenport et al., 2006). To analyze
the processes involved in CD4+ T cell depletion, we compared the
depletion by day 25 with the area under the viral load curve and with
the area under the p11CM+ CD8+ T cell curve from day 0 to 25 (Fig. 3).
These areas under the curves are indicative of the total exposure of
CD4+ T cells to virus and speciﬁc CD8+ T cells, respectively.
Interestingly, CD4+ T cell depletion at day 25 was highly correlated
with total virus exposure up to day 25 (r=0.82, p=2.4×10−6), but not
with total exposure to p11CM+ CD8+ T cells through day 25 (r=0.25,
p=0.23). Although this ﬁnding is suggestive of CD4+ T cell depletion
induced by direct and indirect viral effects, it is not deﬁnitive as other
immune factors not analyzed could contribute to CD4+ Tcell depletion,Fig. 3.What is killing CD4+ T cells? (a) CD4+ T cell depletion correlates much more strongly w
cells produced, i.e. area under the p11CM+ CD8+ T cell curve.such as CD8+ T cell responses to other epitopes, bystander effects, or
antibody-mediated cellular citotoxicity.
Early vs. late challenge led to differences in early viral load levels
Because animals in groups E and F were challenged just one week
after being vaccinated, it is possible that their baseline p11CM+ CD8+ T
cells are qualitatively different from those at baseline in the other
vaccinated groups. In particular we could expect that early after
vaccination, the bulk of antigen-speciﬁc CD8+ T cells may still be
activated. If this is the case, then control of the virus in the groups
challenged at one week should be similar and faster than in the other
groups, since a time delay to activation would not be present. Indeed,
on day 7, groups E and F have a statistically lower viral load than
the vaccinated groups A–D, challenged at 24, 12, 6, and 3 weeks
(p-value=0.027; highlighted in Fig. 1a). This is observed even though
the animals in group F did not receive a boost inoculation. It is
important to note that there is no correlation between the initial
number of p11CM+ CD8+ T cells and the viral load on day 7 in
vaccinated animals, indicating that the initial number of p11CM+
CD8+ T cells is not sufﬁcient to predict early viral control. This suggests
that the functional difference of p11CM+ CD8+ T cells between the
animals infected sooner after vaccination rather than later may
inﬂuence the kinetics of virus early in infection.
Early vs. late challenge and the expansion of p11CM+ CD8+ T cells
At the time of infection, groups challenged early (E, F), versus late
(A–D), have signiﬁcantly more p11CM+ CD8+ T cells expressing Ki67, a
marker of cell proliferation (p=0.0001). Nonetheless, the start time of
observable antigen-speciﬁc CD8+ T cell expansion after infection, ton,
does not statistically differ between groups E–F and groups A–D,
which had lower levels of Ki67 at day 0.
We next looked for differences in the expansion rates of antigen-
speciﬁc cells between groups E and F and groups A–D after expansion
began, using a linear-mixed effects modeling approach (Pinheiro,
2000). We analyzed two estimates of expansion: one incorporating all
points in acute infection between the minimum and the maximum
p11CM+CD8+ T cell count, and the other including only the points
showing the fastest expansion rate (see Methods). In both cases, we
found that p11CM+CD8+ T cells expand more slowly in groups E and F,
with the fastest expansion rate being statistically slower in groups E–F
than in groups A–D (p=0.004).ith the area under the viral load curve than (b) with the total number of speciﬁc CD8+ T
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the early and late challenge groups, we asked if this had any impact on
viral kinetics. To examine the growth in virus, we used two linear
mixed effects models for the change in viral load: one with all points
from day 7 through the viral peak, and one including only the points
deﬁning the fastest expansion. Both models show that groups E and F,
which have slower p11CM+ CD8+ T cell expansion, have faster viral
load expansion after day 7 than groups A–D, with the difference in the
fastest expansion rate reaching statistical signiﬁcance (p=0.003).
Correlation between viral load and p11CM-speciﬁc CD8+ T cell expansion
The results of the previous section seem to indicate that higher
viral loads on day 7 in groups A–D lead to faster expansion of speciﬁc
CD8+ T cells, so we analyzed the correlation between these two
variables in detail. As in our previous work, we found no correlation
between initial p11CM+ CD8+ T cell number and viral load expansion
rate up to day 10 (Davenport et al., 2004). However, here we asked the
converse question and found that higher viral loads at day 7 correlated
with faster expansion rates of p11CM+ CD8+ T cells from day 7 to the
peak (at a median of 12 days) (r=0.45, p=0.029) in the vaccinated
groups (Fig. 4a). Moreover, the viral load at day 7 has a positive
correlation with the area under the p11CM+ CD8+ T cell count curve
(r=0.59, p=0.003), which can be seen as a surrogate for total
production of speciﬁc CD8+ cells (Fig. 4b). That is, the viral load at
day 7 is a good indicator of how many p11CM+ CD8+ T cells will be
produced.
Conclusions
An important consideration in designing a vaccine is to know how
long protection lasts. This is especially true in the case of vaccines
inducing cell mediated immunity, as is the case of many vaccines
being studied against HIV infection, because there is much less
experience with this type of vaccine. Recent vaccination may be
expected to produce higher virus speciﬁc CD8+ T cell counts and may
be expected to lead to better early viral control. However, dissecting
the contribution of greater numbers of speciﬁc CD8+ T cells from
qualitative aspects of the response is difﬁcult. Knowing the time scales
of protective immunity will help inform choices such as vaccination
and boosting schedules. If recent exposure to antigen activates T cells
and enhances the ability of virus speciﬁc CD8+ T cells to control virus
early after infection, perhaps we would need to consider strategies ofFig. 4. Early infection inﬂuences speciﬁc CD8+ T cell production: (a) A higher viral load at day 7
a good indicator of the total number of p11CM-speciﬁc CD8+ T cells that will be produced, amultiple and frequent vaccinations, whichmay require vectors that do
not lead to immunity against later boosts of the vaccine, or even
vaccines including persistent antigens.
Recent CD8+ T cell vaccination trials have met no success in
humans, and the use of models such as SHIV 89.6P in rhesusmacaques
has been questioned as being too pathogenic to aptly model HIV
(Feinberg and Moore, 2002). Although SHIV89.6P may not be an ideal
model of HIV vaccination, it is still much in use (Borsetti et al., 2008;
Koopman et al., 2008; Patterson et al., 2008; Ridolﬁ et al., 2008;
Sadagopal et al., 2008). Moreover, quantitative analyses of SHIV 89.6P
may help us understand its behavior better and, thus it serves as a tool
to probe the immune system and shed light on the relationships
between virus and immune system kinetics.
An important ﬁnding of this study is that the level of immunity, as
measured by the number of antigen-speciﬁc CD8+ T cells at time of
challenge, decays exponentially over at least the ﬁrst 12 weeks post-
boost, then stabilizes from 12 to 24 weeks post-boost. In spite of this,
the “clinical” protection afforded by the vaccine, as measured by
disease progression (i.e., increases in viral load and depletion of CD4+ T
cells), was similar in the different groups of vaccinated monkeys,
including a group that did not receive a boost (Casimiro et al., 2005).
Though the clinical outcome was similar across the vaccinated
groups, we also found important differences. Those monkeys
challenged earlier, at only one week after vaccination (groups E and
F), showed a qualitatively different viral growth than animals
challenged later (groups A–D). The former show early viral control
at a level that has not been seen in settings of later challenge, even
when up to 25% of total CD8+ T cells were virus speciﬁc (Shiver et al.,
2002). Soon after vaccination, many speciﬁc Tcells are expected to still
be activated by antigen, and may also be located in peripheral tissues.
Consistent with this hypothesis, we found higher levels of Ki67, a
proliferation antigen, in the recently vaccinated groups. However, a
more complete characterization of these cells, which was not possible
in this study, needs to be done, including markers of avidity, effector
phenotype, activation, etc.
The lower viral load early after challenge did not lead to lower peak
viral levels. In particular, in the recently vaccinated animals there was
a slower expansion of the p11CM-speciﬁc CD8+ T cells in the second
week of infection, which was associated with faster growth of virus
between day 7 and the day of peak viral load. We speculate that the
virus speciﬁc CD8+ T cell pool in monkeys challenged soon after
vaccination contain more activated cells with less capacity for
additional expansion, which are more efﬁcient at controlling infectionis correlated with a greater expansion rate of p11CM-speciﬁc CD8+ T cells and (b) is also
s measured by the area under the curve of CD8+ T cells.
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animals in groups E and F end up having peak viral loads similar to the
other vaccinated groups.
Virus-speciﬁc CD8+ T cells may moderate viral growth, but viral
levels may also drive virus speciﬁc CD8+ T cell expansion. Overall, the
expansion of these antigen-speciﬁc cells was faster and the total
production of these cells was larger in the animals with higher viral
loads at one week. Consistent with this, the animals in groups E and F,
which had lower viral loads at one week had a slower expansion rate
of p11CM+ CD8+ T cells.
It is remarkable that we found these correlations and differences
between macaques challenged early versus late after vaccination, if
we note that only one speciﬁc aspect of the immune response was
studied (the kinetics of p11CM+ CD8+ T cells). In previous studies we
have shown that subdominant epitopes also have kinetics similar to
the dominant epitope (Davenport et al., 2004; De Boer et al., 2003).
Still, the immune response to the virus is much more complex with
many components that we did not consider, such as the response in
tissues (eg. GALT), the functional activity of the CD8+ T cells, and the
CD4+ speciﬁc response. In particular, it will be interesting to measure
activation and proliferation state of CD4+ T cells early versus late after
vaccination. Unfortunately, in this retrospective kinetic study, we did
not have this information.
In summary and in spite of the caveats just mentioned, our results
indicate that the delay in CD8+ T cell control of virus observed in a
number of studies can be partially overcome in the setting of recent
antigen exposure. Animals vaccinated within a week of challenge had
signiﬁcantly lower early (day 7) viral loads. However, although recent
exposure to antigen is associated with reduced viral load in the ﬁrst
week after infection, viral growth was higher in the second week,
perhaps as a result of the failure of expansion or the death of an
already activated T cell population. This work demonstrates that the
effects of these speciﬁc CD8+ T cells depend not only on their initial
numbers, but also on the level of recent antigen exposure. Whether
the relative control of virus then leads to slower expansion of more
p11CM+ CD8+ Tcells is something that needs more careful quantitative
investigation. Continued modeling and quantitative analyses of
vaccine trials will be invaluable to understanding the early dynamics
and function of CD8+ T cell inducing vaccines.
Methods
Animals and vaccination-challenge protocols
Twenty-eight Mamu-A⁎01+ monkeys were divided into seven
groups of four monkeys each. Five groups were vaccinated with a
replication-incompetent human adenovirus serotype 5 (1011 viral
particles) expressing SIVmac239 gag DNA and received a vaccination
boost 24 weeks later (see Fig. 5 for the experimental protocol). These
groups were then challenged intra-rectally with SHIV-89.6P at 24, 12,
6, 3, and 1 week following the boost (labeled A, B, C, D, and E,Fig. 5. Experimental protocol: 28 monkeys were divided into groups of four, labeled A–
G. Groups A–E received a vaccine then a boost 24 weeks later. These groups were
challenged with SHIV-89.6P at the week corresponding to the slanted arrow. Group F
only received a vaccine at the same time the other groups received their boost and was
challenged one week later. Group G, the control group, was infected with SHIV-89.6P
and received no vaccine or boost.respectively). Group F received no boost and was challenged oneweek
after vaccination. The control group, G, received no vaccination. CD4+ T
cells and viral loads were measured at irregular intervals for
10 months. MHC-tetramer reagents were used to count CD8+ T cells
capable of binding to the immunodominant SIV gag p11CM epitope
presented by theMamu-A⁎01MHC molecule. Ki67 (B56, BD Pharmin-
gen) expression on p11CM+ CD8+ T cells was measured by ﬂow
cytometric methods (Appay and Rowland-Jones, 2002; Champagne et
al., 2001; Oxenius et al., 2001). All vaccinated monkeys, except those
in group B, were euthanized about 325 days following the challenge.
The monkeys in the control group (G) succumbed to infection in a
median of 178 days. Further details on animal care, vaccine and
challenge stock preparation, and cellular assays are provided in
(Casimiro et al., 2005; Shiver et al., 2002).
Statistical analysis
We deﬁne the time of infection as time 0. Virus-speciﬁc CD8+ T cell
expansion rates were calculated by ﬁtting, via linear regression, the
rise of log CD8+ p11CM+ T cells/μL versus time. We used this method to
estimate the expansion rate from the baseline to peak (occurring
around day 12). The same approach was used to estimate the maximal
expansion rate seen in the data: if the expansion slowed before it
reached the peak, we used only the data from the ﬁrst time point
above the baseline to the time before the expansion slowed down. We
deﬁned the start of CD8+ p11CM+ T cell expansion (ton) as the
backward extrapolated time when the maximal expansion rate linear
regression line intersects the baseline CD8+ p11CM+ T cell value; thus,
ton=(log10(T0)−b10)/g10, where T0 is the baseline CD8+ p11CM+ T cell
value on the day prior to infection, b10 is the intercept, and g10 is the
slope found by linear regression (Davenport et al., 2005). Linear mixed
effects models were used to compare CD8+ p11CM+ T cell and viral load
expansion rates, using the lme function in the software package
R (2008). Spearman's rank correlation was used to assess the signi-
ﬁcance of correlations betweenvariables, and theKruskall–Wallis testwas
used to determine whether individual variables differ signiﬁcantly bet-
ween the vaccination groups. Signiﬁcance was assessed at the 0.05 level.
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